Annals of Surgical Oncology

, Volume 20, Supplement 3, pp 716–724 | Cite as

Valproic Acid Sensitizes TRAIL-Resistant Anaplastic Thyroid Carcinoma Cells to Apoptotic Cell Death

  • Hyun-Young Cha
  • Bok-Soon Lee
  • Sam Kang
  • Yoo Seob Shin
  • Jae Won Chang
  • Eun-Sil Sung
  • Yong-Sung Kim
  • Jae Won Choi
  • Jang Hee Kim
  • Chul-Ho Kim
Translational Research and Biomarkers

Abstract

Background

Anaplastic thyroid carcinoma (ATC) is an aggressive human tumor associated with a median survival of 2–6 months. TRAIL, as a ligand of death receptors, is known to induce apoptotic cell death in several cancer cells. However, TRAIL treatment alone is not effective against TRAIL-resistant cancer cells. This study was designed to investigate whether valproic acid (VPA) enhances apoptotic cell death of TRAIL-resistant ATC cells and to identify the mechanism of cell death of ATC cells by combination treatment with VPA and TRAIL.

Methods

To evaluate the cytotoxic effect of TRAIL and/or VPA on ATC cells, we used the MTT assay. The effects of VPA and TRAIL on apoptosis were assessed using FACS analysis (Annexin-V/PI stain) and Western blotting.

Results

The combination of VPA with TRAIL significantly induced apoptotic cell death compared with 8505C and ARO cells treated with TRAIL alone. The protein levels of cleaved caspase-8, -3, and PARP were increased in VPA and TRAIL co-treated ARO cells. The combination induced the activation of JNK and the phosphorylation of FADD and c-Jun but not p38. However, pretreatment with caspase inhibitors reduced the expression of cleaved caspase-8, -3, and PARP in co-treated ARO cells. SP600125 remarkably reduced the expression of cleaved caspase-8, -3, and PARP and the phosphorylation of FADD and c-Jun, as well as apoptotic cell death.

Conclusions

VPA sensitized TRAIL-resistant ATC cells to apoptotic cell death through involvement of the JNK pathway. Thus, the combination of VPA and TRAIL may be a promising therapy for ATC.

References

  1. 1.
    Vini L, Harmer C. Management of thyroid cancer. Lancet Oncol. 2002;3(7):407–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Tan RK, Finley RK 3rd, Driscoll D, Bakamjian V, Hicks WL Jr, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck. 1995;17(1):41–7; discussion 47–8.Google Scholar
  3. 3.
    Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol. 2003;15(1):78–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Conticello C, Adamo L, Giuffrida R, et al. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J Clin Endocrinol Metab. 2007;92(5):1938–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Arlot-Bonnemains Y, Baldini E, Martin B, et al. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr Relat Cancer. 2008;15(2):559–68.PubMedCrossRefGoogle Scholar
  6. 6.
    Libertini S, Abagnale A, Passaro C, et al. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr Relat Cancer. 2011;18(1):129–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Wunderlich A, Roth S, Ramaswamy A, et al. Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer. Endocrine. 2012;42(3):637–46.PubMedCrossRefGoogle Scholar
  8. 8.
    Ahmad M, Shi Y. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene. 2000;19(30):3363–71.PubMedCrossRefGoogle Scholar
  9. 9.
    LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10(1):66–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol. 2003;13(2):135–47.PubMedCrossRefGoogle Scholar
  11. 11.
    Sung ES, Park KJ, Choi HJ, Kim CH, Kim YS. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp Cell Res. 2012;318(13):1564–76.PubMedCrossRefGoogle Scholar
  12. 12.
    Kahana S, Finniss S, Cazacu S, et al. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions. Cell Signal. 2011;23(8):1348–57.PubMedCrossRefGoogle Scholar
  13. 13.
    Sung ES, Kim A, Park JS, Chung J, Kwon MH, Kim YS. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis. 2010;15(10):1256–69.PubMedCrossRefGoogle Scholar
  14. 14.
    Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther. 2010;9(12):3254–66.PubMedCrossRefGoogle Scholar
  15. 15.
    Iacomino G, Medici MC, Russo GL. Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis. Anticancer Res. 2008;28(2A):855–64.PubMedGoogle Scholar
  16. 16.
    Brautigam K, Biernath-Wupping J, Bauerschlag DO, et al. Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines. J Cancer Res Clin Oncol. 2011;137(5):875–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Munshi A, McDonnell TJ, Meyn RE. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2002;50(1):46-52.PubMedCrossRefGoogle Scholar
  18. 18.
    Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene. 2004;23(37):6261–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Nightingale KP, O’Neill LP, Turner BM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Gen Dev. 2006;16(2):125–36.PubMedCrossRefGoogle Scholar
  20. 20.
    Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Gen Dev. 1999;9(1):40–8.CrossRefGoogle Scholar
  21. 21.
    Csordas A. On the biological role of histone acetylation. Biochem J. 1990;265(1):23–38.PubMedGoogle Scholar
  22. 22.
    Fulda S. Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis. Exp Cell Res. 2012;318(11):1208–12.PubMedCrossRefGoogle Scholar
  23. 23.
    Perego P, Zuco V, Gatti L, Zunino F. Sensitization of tumor cells by targeting histone deacetylases. Biochem Pharmacol. 2012;83(8):987–94.PubMedCrossRefGoogle Scholar
  24. 24.
    Frew AJ, Lindemann RK, Martin BP, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA. 2008;105(32):11317–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269(1):7–17.PubMedCrossRefGoogle Scholar
  26. 26.
    Lee BS, Cha HY, Shin YS, Kim YS, Kim CH. AY4, an agonistic anti-death receptor 4 monoclonal antibody, induces apoptotic cell death in anaplastic thyroid cancer cells via down-regulation of Bcl-xL with reactive oxygen species generation. Endocr Relat Cancer. 2013;20:283–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Lee BS, Kang SU, Hwang HS, et al. An agonistic antibody to human death receptor 4 induces apoptotic cell death in head and neck cancer cells through mitochondrial ROS generation. Cancer Lett. 2012;322(1):45–57.PubMedCrossRefGoogle Scholar
  28. 28.
    Lim YC, Park HY, Hwang HS, et al. (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett. 2008;271(1):140–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Kim CH, Koh YW, Han JH, et al. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck. 2010;32(12):1655–64.PubMedGoogle Scholar
  30. 30.
    Tang F, Tang G, Xiang J, Dai Q, Rosner MR, Lin A. The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol. 2002;22(24):8571–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Muscarella DE, Bloom SE. The contribution of c-Jun N-terminal kinase activation and subsequent Bcl-2 phosphorylation to apoptosis induction in human B-cells is dependent on the mode of action of specific stresses. Toxicol Appl Pharmacol. 2008;228(1):93–104.PubMedCrossRefGoogle Scholar
  32. 32.
    Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37–40.PubMedCrossRefGoogle Scholar
  33. 33.
    Luong QT, O’Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res. 2006;12(18):5570–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Sonnemann J, Gange J, Kumar KS, Muller C, Bader P, Beck JF. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Investig New Drugs. 2005;23(2):99–109.CrossRefGoogle Scholar
  35. 35.
    Chopin V, Slomianny C, Hondermarck H, Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors’ signaling and requires P21(waf1). Exp Cell Res. 2004;298(2):560–73.PubMedCrossRefGoogle Scholar
  36. 36.
    Fan M, Goodwin ME, Birrer MJ, Chambers TC. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res. 2001;61(11):4450–8.PubMedGoogle Scholar
  37. 37.
    Sharma V, Koul N, Joseph C, Dixit D, Ghosh S, Sen E. HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J Cell Mol Med. 2010;14(8):2151–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Xiao D, Pinto JT, Soh JW, et al. Induction of apoptosis by the garlic-derived compound S-allylmercaptocysteine (SAMC) is associated with microtubule depolymerization and c-Jun NH(2)-terminal kinase 1 activation. Cancer Res. 2003;63(20):6825–37.PubMedGoogle Scholar
  39. 39.
    Benoit M, Dormond-Meuwly A, Demartines N, Dormond O. Targeting the JNK signaling pathway potentiates the antiproliferative efficacy of rapamycin in LS174T colon cancer cells. J Surg Res. 2011;167(2):e193–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Higuchi H, Grambihler A, Canbay A, Bronk SF, Gores GJ. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem. 2004;279(1):51–60.PubMedCrossRefGoogle Scholar
  41. 41.
    Hwang MK, Ryu BJ, Kim SH. AW00179 potentiates TRAIL-mediated death of human lung cancer H1299 cells through ROS-JNK-c-Jun-mediated up-regulation of DR5 and down-regulation of anti-apoptotic molecules. Amino Acids. 2012;43(4):1679–87.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Hyun-Young Cha
    • 1
    • 2
  • Bok-Soon Lee
    • 1
    • 2
  • Sam Kang
    • 1
    • 2
  • Yoo Seob Shin
    • 1
    • 2
  • Jae Won Chang
    • 1
    • 2
  • Eun-Sil Sung
    • 2
    • 3
  • Yong-Sung Kim
    • 2
    • 3
  • Jae Won Choi
    • 1
    • 2
  • Jang Hee Kim
    • 4
  • Chul-Ho Kim
    • 1
    • 2
  1. 1.Department of Otolaryngology, School of MedicineAjou UniversitySuwonKorea
  2. 2.Center for Cell Death Regulating Biodrug, School of MedicineAjou UniversitySuwonKorea
  3. 3.Department of Molecular Science and Technology, School of MedicineAjou UniversitySuwonKorea
  4. 4.Department of Pathology, School of MedicineAjou UniversitySuwonKorea

Personalised recommendations